Navigation Links
Celladon Corporation Announces Appointment of Gregg Alton and Graham Cooper to its Board of Directors
Date:9/10/2013

SAN DIEGO, Sept. 10, 2013 /PRNewswire/ -- Celladon Corporation, a clinical-stage biotechnology company focused on developing novel therapies by applying its leadership position in the field of SERCA enzymes, announced today it has appointed Gregg Alton and Graham Cooper to its Board of Directors.

"We are pleased to appoint Gregg and Graham to our Board of Directors," commented Krisztina Zsebo Ph.D., President and CEO of Celladon.  "They each bring extensive experience in the biotechnology industry and we expect they will provide valuable strategic contributions to our Board."

Gregg Alton is currently executive vice president of corporate and medical affairs and chief compliance officer at Gilead Sciences, a position he has held since August 2009.  From 2000 to 2009, Mr. Alton held various positions with Gilead, including associate general counsel, general counsel, vice president and senior vice president.  Earlier in his career, Mr. Alton was an associate at the law firms of Cooley LLP and Mintz, Levin, Cohn, Ferris, Glovsky & Popeo, P.C. where he advised and represented biotechnology clients in a wide range of corporate transactions.  Mr. Alton currently serves on the boards of directors of Gilead Healthcare PAC, the Gilead Foundation, the AIDS Institute and BayBio, a San Francisco life sciences industry organization.  He also serves as a member of the Advisory Board of the University of California, San Francisco Global Health Group and the Dean's Advisory Council at Stanford Law School.  Mr. Alton received a B.A. from the University of California, Berkeley and a J.D. from Stanford Law School. 

Graham Cooper is currently chief financial officer at Receptos Corporation, a biopharmaceutical company focused on therapeutics for immune disorders. Mr. Cooper served as executive vice president of finance and chief financial officer at Geron Corporation during 2012, a biopharmaceutical company focused on cancer therapies.  From 2006 to 2011, Mr. Cooper served as senior vice president, chief financial officer and treasurer of Orexigen Therapeutics, Inc., a biotechnology company focused on obesity therapeutics.  Previously, Mr. Cooper held positions of increasing responsibility, including director, health care investment banking, at Deutsche Bank Securities, a leading global investment bank, where he was responsible for executing and managing a wide variety of financing and merger and acquisition transactions in the life sciences field.  Previously, he worked in audit and accounting services at Deloitte & Touche LLP, an independent registered public accounting firm, and was previously a C.P.A.  Mr. Cooper holds a B.A. in economics from the University of California, Berkeley and an M.B.A. from the Stanford Graduate School of Business. 

About Celladon
We are a clinical-stage biotechnology company applying our leadership position in the field of calcium dysregulation by targeting SERCA enzymes to develop novel therapies for diseases with tremendous unmet medical needs. Sarco/endoplasmic reticulum Ca2+-ATPase, or SERCA, enzymes are a family of enzymes that play an integral part in the regulation of intra-cellular calcium in all human cells. Calcium dysregulation is implicated in a number of important and complex medical conditions and diseases, such as heart failure, diabetes and neurodegenerative diseases. Our therapeutic portfolio for diseases characterized by SERCA enzyme deficiency includes both gene therapies and small molecule compounds. MYDICAR, our most advanced product candidate, uses gene therapy to target SERCA2a, which is an enzyme that becomes deficient in patients with heart failure. In a 39-patient randomized, double-blind, placebo-controlled phase 2a trial in patients with systolic heart failure, which we refer to as CUPID 1, MYDICAR was found to be safe and well-tolerated, reduced heart failure-related hospitalizations, improved patients' symptoms, quality of life and serum biomarkers, and improved key markers of cardiac function predictive of survival, such as end systolic volume. Based on these results, as well as our previous preclinical studies and clinical trials, we advanced MYDICAR to a 200-patient randomized, double-blind, placebo-controlled international Phase 2b trial in patients with systolic heart failure, which we refer to as CUPID 2. We expect to complete enrollment of CUPID 2 in the first quarter of 2014 and announce results in mid-2015.


'/>"/>
SOURCE Celladon Corporation
Copyright©2012 PR Newswire.
All rights reserved

Related biology technology :

1. Celladon Corporation Announces Pre-clinical Study Demonstrating Inhalable MYDICAR Reverses Pulmonary Arterial Hypertension (PAH)
2. Celladon Corporation Selected as Winner of Red Herrings "Top 100 North America Tech Startup"
3. Celladon Corporation and SIRO Clinpharm Announce Presentation at "Statisticians in the Pharmaceutical Industry International Conference"
4. Celladon Corporation To Present at BioCentury Future Leaders in the Biotech Industry Conference
5. Celladon Corporation Named a 2012 Fierce 15 Company by FierceBiotech
6. China Cord Blood Corporation Reports Financial Results for the First Quarter of Fiscal 2014
7. China Cord Blood Corporation to Report First Quarter of Fiscal 2014 Financial Results
8. Verenium Corporation To Announce Second Quarter 2013 Financial Results
9. United Therapeutics Corporation Reports Second Quarter 2013 Financial Results
10. Techne Corporation Announces Acquisition Completion
11. United Therapeutics Corporation to Announce Second Quarter 2013 Financial Results Before Market Open on Thursday, July 25, 2013
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/20/2017)... , January 20, 2017 Stock-Callers.com ... conditions have influenced the most recent performances of select ... (NASDAQ: RGLS ), Abeona Therapeutics Inc. (NASDAQ: ... TBPH ), and Sage Therapeutics Inc. (NASDAQ: ... by Grand View Research, global Biotech market size is expected to ...
(Date:1/20/2017)... YORK , January 20, 2017 ... Organization, cancer is one of leading causes of death ... 2012. Although the number of cancer related deaths increased ... 1990. Rising in incidence rate of various cancers continues ... to a research report by Global Market Insights, Inc. ...
(Date:1/19/2017)... Research and Markets has announced the addition of the ... Global Opportunity Analysis and Industry Forecast, 2014-2022" report to their ... Cancer ... reach $15,737 million by 2022 from $6,521 in 2015, growing at ... Omic technologies segment accounted for more than half of the revenue ...
(Date:1/19/2017)... Ky. and HOUSTON ... Inc. ("NX Prenatal") today announced the formation of ... together leading clinicians and industry veterans who enhance ... company as it accelerates development of its novel ... to provide medical, clinical and strategic guidance for ...
Breaking Biology Technology:
(Date:1/18/2017)... MINNETONKA, Minn. , Jan. 18, 2017 /PRNewswire/ ... eClinical technology company that supports the entire spectrum ... 2016 has been another record-breaking year for the ... and market interest in MedNet,s eClinical products and ... to the tremendous marketplace success of ...
(Date:1/12/2017)... 2017  New research undertaken by Fit Small Business ... 1,000 participants were simply asked which office technology had they ... consider standard issue.  Insights on what will be ... from futurists and industry leaders including Penelope Trunk , ... Some of these findings included; ...
(Date:1/11/2017)... , Jan. 11, 2017  Michael Johnson, co-founder of Visikol Inc. ... Group, Inc., has been named to the elite "Forbes 30 Under ... one of 600 people in 20 fields nationwide to be recognized ... the 15,000 applicants were selected. ... He is currently a PhD candidate at Rutgers University. ...
Breaking Biology News(10 mins):